经皮穿刺微波凝固联合替吉奥治疗胃癌肝转移的疗效观察

目的观察经皮穿刺微波凝固治疗（PMCT）术后联合替吉奥胶囊（S-1）治疗胃癌肝转移的疗效。方法选择本科2009年2月~2012年3月收治的56例胃癌根治术后肝转移患者,分为PMCT术后联合替吉奥组（实验组,n=28）和单用PMCT组（对照组,n=28）。实验组PMCT术后口服替吉奥胶囊每日50mg/m2,连续给药14d,停药7天,共化疗6个疗程。结果实验组和对照组治疗结束时完全缓解分别为64.28%（18/28）和32.14%（9/28）,部分缓解分别为25%（7/28）和21.42%（6/28）,稳定分别为7.14%（2/28）和32.14%（9/28）,有效率89.29%（25/28）和53.57%（15/28）,两组相比均有统计学差异（P〈0.05）。毒副反应主要为骨髓抑制、胃肠道反应等。结论胃癌根治术后肝转移患者PMCT术后联合替吉奥化疗可提高患者术后生存率且毒副反应较轻,是胃癌根治术后伴肝转移有益的辅助治疗方案。

Combined Percutaneous Microwave Coagulation Therapy and S-1in the Treatment of Liver Metastases from Gastrc cancer

Objective To evaluate the effect of percutaneous microwave coagulation therapy （PMCT） combined with S-1 in the treatment of liver metastases from gastric cancer. Methods From February 2009 to March 2012 6 patients with liver metastases from gastri cancer were randomly divided into treatment group （PMCT and S-1） and control group （only PMCT）. In the treatment group,S-1 was administered 50 mg/m2/d for 14 consecutive days fol- lowing a 1-week rest, 3 weeks for a cycle. The effects were evaluated after 6 cycles. Results There were 18 （64.28%） CR,7（25%） PR, 2 （7.14%） SD in the treatment group, and 9（32.14%） CR,6（21.42%） PR, 9 （32.14%） SD in the control group. The overall response rates were 89.29% and 53. 574%, respectively. There was significant difference between two groups （P〈0.05）. Major adverse reactions were myelosuppressive and gastroin- testinal toxicities. Conclusion PMCT combined with S-1 shows well tolerance and good effect as a new therapy for patients with liver metastases from gastric cancer.